Charles Wu
Chief Tech/Sci/R&D Officer at Beijing Continent Pharmaceutical Co., Ltd.
Net worth: - $ as of 2024-05-30
Charles Wu active positions
| Companies | Position | Start | End |
|---|---|---|---|
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Chief Tech/Sci/R&D Officer | 2019-12-31 | - |
Career history of Charles Wu
Former positions of Charles Wu
| Companies | Position | Start | End |
|---|
Training of Charles Wu
| University of Science & Technology of China | Undergraduate Degree |
| University of Maryland | Doctorate Degree |
| Tulane University (Louisiana) | Masters Business Admin |
Statistics
International
| China | 3 |
| United States | 3 |
Operational
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
- Stock Market
- Insiders
- Charles Wu
- Experience
